Scorpius Holdings, Inc. (SCPX)
NYSEAMERICAN: SCPX · Real-Time Price · USD
0.670
+0.010 (1.52%)
At close: Nov 20, 2024, 4:00 PM
0.684
+0.014 (2.06%)
After-hours: Nov 20, 2024, 7:50 PM EST

Company Description

Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.

The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities.

It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.

The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024.

Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

Scorpius Holdings, Inc.
Scorpius Holdings logo
Country United States
Founded 2008
IPO Date Jul 24, 2013
Industry Biotechnology
Sector Healthcare
Employees 84
CEO Jeffrey Wolf

Contact Details

Address:
627 Davis Drive, Suite 300
Morrisville, North Carolina 27560
United States
Phone 919 240 7133
Website scorpiusbiologics.com

Stock Details

Ticker Symbol SCPX
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001476963
ISIN Number US42237K4094
Employer ID 26-2844103
SIC Code 2834

Key Executives

Name Position
Jeffrey Alan Wolf J.D. Founder, Chairman, President and Chief Executive Officer
William L. Ostrander Chief Financial Officer, Controller and Secretary
Dr. Justin Stebbing FRCP, FRCPath, M.A., M.D., Ph.D. Chief Medical Advisor and Member of Scientific and Clinical Advisory Board
Colonel George E. Peoples Jr., F.A.C.S., M.D. Chief Medical Advisor
Ania Szymanska Site Head of Quality
Joe Payne President and Chief Operating Officer of Scorpius BioManufacturing
Nicole Temple Senior Manager and Head of Program Management

Latest SEC Filings

Date Type Title
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 8-K Current Report
Sep 26, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 6, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 26, 2024 8-K Current Report
Aug 19, 2024 10-Q Quarterly Report
Aug 19, 2024 8-K Current Report
Aug 16, 2024 424B4 Prospectus
Aug 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Aug 9, 2024 8-K Current Report